Looks at whether the selection of erlotinib for the treatment of gliomas should be based on epidermal growth factor receptor (EGFR) and Akt analysis. Details of a phase I study of glioma patients treated with erlotinib; Association of EGFR gene amplification and expression with response to erlotinib in glioblastoma multiforme.